Kimi K2.5 better than Opus 4.6 on hallucination benchmark in pharmaceutical domain
In a specialized test, Kimi K2.5 showed a significantly lower hallucination rate than top commercial models.
Deep Dive
Moonshot AI's Kimi K2.5 model outperformed Anthropic's Claude Opus 4.6 in a new hallucination benchmark for the pharmaceutical domain. The Placebo-Bench tested 7 recent models on realistic pharma data. Claude Opus 4.6 had the highest hallucination rate, often inventing clinical protocols not in the source data. Kimi K2.5 performed much better, though still imperfect, showing specialized models can reduce critical errors in high-stakes fields.
Why It Matters
For life sciences and healthcare, this highlights which AI models are safer for analyzing sensitive clinical data without inventing facts.